CT 2584

Drug Profile

CT 2584

Alternative Names: Apra

Latest Information Update: 25 Jun 2002

Price : $50

At a glance

  • Originator Cell Therapeutics
  • Developer Cell Therapeutics; Shire Pharmaceuticals Group
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Lysophosphatidic acid acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 31 Dec 2001 Discontinued - Phase-II for Ovarian cancer in USA (IV-infusion)
  • 31 Dec 2001 Discontinued - Phase-II for Sarcoma in USA (IV-infusion)
  • 31 Dec 2001 Discontinued - Phase-II for Cancer in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top